B
BenevolentAI
BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company
At a glance
- Status
- Listed
- Founded
- 2013
- Headquarters
- London, United Kingdom
- Listing
- Public via SPAC 2021
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later6 investors entered at this stage
- WMWoodford Investment Management
- TNTech Nation
- LPLansdowne Partners
Temasek
Goldman Sachs- LULundbeck
Source: Dealroom Talent Intelligence.
Alumni founders
Former BenevolentAI employees who went on to found companies, sorted by Dealroom signal score.
Benjamin TenmannUnited States
SBSable BioEst. 2023
Alex de GiorgioUnited Kingdom
Anna Muñoz FarréUnited Kingdom
Jeffrey NgUnited Kingdom
KTKheiron Medical TechnologiesEst. 2016Global footprint
team presence
across markets
Patents
29 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about BenevolentAI on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BenevolentAI on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


